CM
HRMY icon

Castleark Management’s Harmony Biosciences HRMY Stock Holding History

Castleark Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80,140
Closed -$4.42M – 304
2022
Q4 		$4.42M Buy
+80,140
New +$4.41M 0.23% 103

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Castleark Management's HRMY Position: Q1 2023 in Review

Castleark Management sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 80,140 shares — an estimated $4.42M sold.

Castleark Management first reported a position in HRMY in Q4 2022 and held it in 1 quarter. The position peaked at $4.42M in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • Castleark Management reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • Castleark Management sold 80,140 Harmony Biosciences shares in Q1 2023, an estimated $4.42M.
  • Castleark Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 1 quarter.
  • Castleark Management's Harmony Biosciences position peaked at $4.42M in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Castleark Management's 13F filing for Q1 2023, filed 16 May 2023.